There is a concerted research effort to investigate brain mechanisms underlying addiction processes that may predicate the development of new compounds for treating addiction. One target is the brain's opioid system, because of its role in the reinforcing effects of substances of abuse. Substance-dependent populations have increased numbers of the mu opioid receptor (MOR) in fronto-striatal regions that predict drug relapse, and demonstrate disturbances in these regions during the processing of non-drug rewards. Naltrexone is currently licensed for alcohol and opiate dependence, and may remediate such disturbances through the blockade of MORs in fronto-striatal reward circuitry. Therefore, we examined the potential acute modulating effects of naltrexone on the anticipation of, and instrumental responding for, non-drug rewards in long-term abstinent alcoholics, alcoholic poly substance-dependent individuals and controls using a monetary incentive delay (MID) task during a randomized double blind placebo controlled functional MRI study. We report that the alcoholic poly substance-dependent group exhibited slower and less accurate instrumental responding compared to alcoholics and controls that was less evident after acute naltrexone treatment. However, naltrexone treatment was unable to remediate disturbances within fronto-striatal regions during reward anticipation and 'missed' rewards in either substance-dependent group. While we have not been able to identify the underlying neural mechanisms for improvement observed with naltrexone in the alcoholic poly-substance dependent group, we can confirm that both substance-dependent groups exhibit substantial neural deficits during an MID task, despite being in long-term abstinence.
INTRODUCTION
Substance dependence, particularly to alcohol, continues to be a major cause of harm to individuals and society (Nutt, King, & Phillips 2010) . Identifying the substrates of addiction in an attempt to elucidate potential neural targets for future treatment development in substance dependence remains a major challenge in neuroscience. One such neural target is the brain's opioid system, given its interactions with the dopamine (DA) system of the brain (Solinas et al. 2004) , and its role in the reinforcing effects of alcohol and other substances of abuse (Spreckelmeyer et al. 2011; Colasanti et al. 2012; Mick et al. 2014) .
Mu opioid receptor (MOR) numbers are reported to be significantly elevated in alcoholic patients in early abstinence (Heinz et al. 2005) , particularly in the ventral striatum (VS), with increased MOR availability found to correlate with alcohol craving (Williams et al. 2009 ). Similarly, cocaine abusers in early abstinence have increased numbers of MORs within fronto-striatal regions (Gorelick et al. 2005) , which have been found to predict relapse (Gorelick et al. 2008) . A similar pattern has been reported in opiate abstinence (Zubieta et al. 2000; Williams et al. 2007) . There is also good evidence that MOR blockade is effective in promoting substance abstinence (Krystal et al. 2001; Srisurapanont & Jarusuraisin 2005; Grassi et al. 2007) . Therefore, disturbances to the brain's opioid system during early abstinence make it a viable target for protection against potential alcohol and drug relapse.
Substance abusers, particularly alcoholics, may still be at risk for relapse in long-term abstinence because of ongoing and latent disturbances in the brain's opioid system. Opioid disturbances within DA fronto-striatal reward circuitry may confer an ongoing risk for relapse to drug rewards if there is a diminished incentive value of, and motivation to procure, non-drug rewards. Naltrexone is currently licensed for alcohol dependence and may remediate these disturbances by restoring some balance within key fronto-striatal networks that are critical for optimizing the incentive value and attainment of non-drug rewards. The current study, therefore, investigated the effects of acute MOR blockade with naltrexone on fronto-striatal-dependent reward processing in alcoholics and polysubstance-dependent individuals who were in extended abstinence. We hypothesized that (1) alcoholic and polysubstance-dependent groups, compared to controls, would demonstrate disturbances within fronto-striatal regions in response to the prediction of potential non-drug rewards and (2) acute MOR blockade with naltrexone would have an ameliorating effect on these neural disturbances, possibly providing a credible therapeutic biomarker for treating deficiencies in non-drug reward processing that may trigger relapse to addictive behaviour.
MATERIAL AND METHODS

Participants
This was a randomized double blind placebo controlled multi-centre study involving three study sites in the United Kingdom (Imperial College, Cambridge and Manchester-ICCAM). For a more detailed description of the ICCAM Platform, see Paterson et al. (2015) . Inclusion criteria were individuals who met DSM-IV criteria for current or prior alcohol dependence (Alcohol minus ), or alcohol plus (Alcohol plus ) another substance of dependence (e.g. amphetamines, benzodiazepines, cocaine, opiates) and who would be abstinent for at least 4 weeks prior to the experimental sessions. There was no upper limit for abstinence length. All participants were aged 21 to 64. In the current study, the Alcohol minus group was made up of 21 abstinent alcoholics, with the Alcohol plus group comprised of 25 abstinent alcoholic polysubstancedependent individuals (having met criteria for dependence to alcohol plus one or more other substances of dependence). The Alcohol plus group was made up of six abstinent alcoholics with cocaine dependence; six with cocaine and opiate dependence; four with amphetamine, cocaine and opiate dependence; two with just opiate dependence; one with amphetamine, cocaine and solvent dependence; one with benzodiazepine, cocaine and opiate dependence; one with cocaine and gamma hydroxybutyrate dependence; one with benzodiazepine and opiate dependence; one with amphetamine and cocaine dependence; one with benzodiazepine and cocaine dependence; and one with just amphetamine dependence. The healthy control group was made up of 35 participants with no previous history of substance abuse, as assessed using the ASSIST and timeline follow-back. All participants were required to provide a negative breath alcohol test and a negative urine sample for various drugs of abuse on both experimental days (screening for the presence of amphetamines, benzodiazepines, cannabinoids, cocaine and opiates).
Exclusion criteria included (1) current use of regular prescription or non-prescription medication that could not be stopped for the study duration, or would interfere with study integrity or subject safety (including but not limited to antipsychotics, anticonvulsants, antidepressants, disulfiram, acamprosate, naltrexone, varenicline); (2) current primary axis I diagnosis, past history of psychosis (unless drug-induced); (3) current or past history of enduring severe mental illness (e.g. schizophrenia, bipolar affective disorder); (4) other current or past psychiatric history that, in the opinion of a psychiatrist, contraindicated participation; (5) history or presence of a significant neurological diagnosis that may have influenced the outcome or analysis of the results (including but not limited to stroke, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, clinically significant head injury); (6) claustrophobia or unable to lie still in the MRI scanner for up to 90 minutes; and (7) presence of a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre-MRI questionnaire. Secondary or lifetime history of depression or anxiety was permitted in both substance abusers and healthy controls because these are very common psychiatric disorders.
Experimental visits
At the randomized placebo and naltrexone experimental visits, an eligibility check was performed. Participants' intervening drug use and concomitant medication were checked, and participants completed alcohol breath, pregnancy and urine drugs of abuse screening tests. Cigarette smokers in all groups smoked ad lib approximately 60 minutes prior to scanning in order to avoid the potential confounds of withdrawal and/or craving during scanning.
Medications
Drug preparation, labelling and packaging were performed by UCLH Pharmacy Manufacturing Unit. Placebo was Vitamin C (100 mg, supplier: Sigma, manufacturer: Norbrook), and naltrexone (50-mg Nalorex®-manufacturer-Bristol-Myers Squibb) was prepared and packaged according to Investigational Medicinal Product guidelines. The maximum naltrexone plasma concentration after an acute 50-mg dose is 0.5-3 hours (Meyer et al. 1984) . Therefore, participants were dosed 2 hours prior to each experimental scan session to ensure high MOR occupancy during testing. Naltrexone and placebo medications were supplied in identical white opaque bottles and administered by independent nursing staff, such that both researcher and participant remained blinded.
Monetary incentive delay task (MID)
We used a 'monetary incentive delay task' (MID), which was based on that originally employed by Knutson (Knutson et al. 2001) . While being scanned on the placebo and naltrexone experimental sessions, participants performed the MID task, during which they anticipated potential monetary gain, loss or no potential monetary outcome. During each trial, participants viewed one of three symbols (a cue) that indicated the potential to win fifty pence (square containing an ascending arrow), lose fifty pence (square containing a descending arrow) or experience no financial outcome (square containing a horizontal line-here referred to as a neutral trial). Each cue was presented for one second, with a variable duration (2-4 seconds) for the subsequent anticipation period. Following the anticipation period, participants made a button press response upon the presentation of a visual target (star located within a circle). Following their response to the visual target, participants received feedback (1500 ms) as to whether they were successful or unsuccessful ('Hit' or 'Miss', respectively) on each trial, and also saw a running total of their winnings up to that point in the task. Following the feedback, there was an end fixation period (3-5 seconds) before the commencement of the next trial.
Because the primary objective of this study was to examine the neural correlates of reward processing, we chose to use a smaller number of loss trials in an attempt to increase the incentive salience of win trials during the task. Consequently, there were a total of 18 'win', 6 'lose' and 18 'neutral' trials on each run of the task. The MID task was additionally tailored to adapt to the visual target reaction time of each participant by using a staircase algorithm, such that the presentation of the visual target became shorter as performance improved during the experiment. This staircase algorithm enabled us to set a limit on the success rate of each participant (~66 percent), which additionally served to incentivize participants to engage in the task. Participants were instructed to maximize their winnings and were told that they would receive them at the end of the study. Dependent measures were percentage accuracy and mean reaction time (milliseconds) to the visual target on each of the MID trials. There were two functional MRI runs of the task (432 seconds each). The task was programmed using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).
Functional MRI (fMRI) data acquisition
All centres operated MRI machines with a main magnetic field of 3 tesla (T). Centres in London and
Cambridge operated nominally identical 3 T Siemens Tim Trio systems running the syngo MR B17 software with a Siemens 32 channel receive-only phased-array head coil. The Manchester centre operated a 3 T Philips Achieva running version 2.6.3.5 software and an eight element SENSE head coil. For anatomical images, 160 high-resolution T1-weighted anatomic MPRAGE axial images (FOV 256 mm, thickness 1.0 mm, voxel size 1.0 × 1.0 × 1.0) were acquired (total duration 303 seconds). Functional data were acquired using a T2* weighted echo-planar imaging sequence collecting 36 non-contiguous (0 percent gap) 3.0-mm axial slices covering the entire brain (TE = 31 ms, TR = 2000 ms, FOV 225 mm, 64 × 64 mm matrix size in Fourier space). The two runs of the MID task produced a total of 432 volumes of functional MRI data.
MID fMRI data analyses
Data pre-processing and statistical analysis were conducted using fMRI Expert Analysis Tool (FEAT) from the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl). Prestatistical processing was as follows: motion correction utilizing FMRIB's Linear Image Registration Tool (MCFLIRT); non-brain matter removal using Brain Extraction Tool (BET); spatial smoothing with a 5-mm full-width half maximum Gaussian kernel; mean-based intensity normalization; nonlinear high-pass temporal filtering (Gaussian-weighted least squares straight line fit, with sigma = 25.0 seconds). The six rigid body movement parameters were also included as regressors in the model in FSL FEAT. For each participant, first level whole-brain mixedeffects analyses were performed by modelling the MID anticipation periods (i.e. Neutral, Win) as explanatory variables within the context of the general linear model on a voxel-by-voxel basis (variable boxcar functions for the cue + variable anticipation period regressors were convolved with the haemodynamic response function). The win and neutral outcome periods ('Hit' and 'Miss') were also modelled (stick functions for 'hit' and 'miss' trial period regressors were convolved with the haemodynamic response function). During these first level analyses, the win anticipation > neutral anticipation, win hit > neutral hit and win miss > neutral miss contrasts was formulated. Owing to the small number of loss trials in the current task, the loss cue + anticipation and outcome periods were regressed out of the functional time series as conditions of no interest. The end fixation period of the task served as the implicit baseline. Registration was conducted through a two-step procedure, whereby EPI images were first registered to the high-resolution T1 structural image, then into standard (Montreal Neurological Institute, MNI avg152 template) space, with 12-parameter affine transformations.
Two (Group: alcohol minus & alcohol plus combined versus control) by two (Drug: placebo versus naltrexone) whole brain cluster-based repeated measures ANOVA analyses were performed as part of a higher-level mixedeffects analysis on the win anticipation > neutral anticipation, win hit > neutral hit and win miss > neutral miss contrasts. These higher-level analyses were conducted using FLAME (FMRIB's Local Analysis of Mixed Effects). Cluster (Gaussianized F) statistical images were determined by Z > 2.3 with a corrected cluster significance threshold of p < 0.05. This ANOVA analysis produced a total of three (i.e. drug effect, group effect, drug × group interaction) zF statistical images.
Other statistics
Between groups demographics (see Table 1 ) were examined using Kruskal-Wallis (gender distribution and drug order) or one-way ANOVA analyses. For analyses conducted on the MID behavioural data, we used a three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) by two (Condition: neutral versus win) repeated measures ANOVA analyses. We also conducted a three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA on an index of the relative motivational value (RMV). This value is based on the ratio of mean reaction times to the target on neutral trials compared to that on win trials-i.e. RT neutral /RT win . Here a value >1 reflects a higher relative value of monetary incentives (Sescousse, Li, & Dreher 2015) , and which more closely reflects the contrasts in the incentive value of these conditions computed during the functional MRI analyses. We extracted the mean BOLD signal change from the group zF-statistic ANOVA clusters and conducted three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA analyses to explore the direction of the effects observed in the cluster- Table 1 Demographic variables for the control, alcohol minus and alcohol plus groups. Age *p < 0.05-alcohol minus > alcohol plus & control; Edu **p < 0.01-alcohol plus < control; IQ *p < 0.05-alcohol plus < control; Alcohol Exposure ***p < 0.001 control < alcohol minus & *p < 0.05-alcohol plus < alcohol minus ; Cigarette Use **p < 0.01-alcohol plus > control; Cannabis Use ***p < 0.001-alcohol plus > alcohol minus & control. Also shown are the months of abstinence from alcohol in all three groups and additional substances of dependence in the alcohol plus group. Data are expressed as means ± SEM. Ranges of substance abstinence are also provided in parentheses. based analyses. All analyses were conducted using the Statistical Package for the Social Sciences (SPSS Inc., Chicago). Table 1 shows the between group demographics for the control, alcohol minus and alcohol plus groups. The groups significantly differed on most of the measures reported herein, including age (alcohol minus > alcohol plus & control), years of education (alcohol plus < control), IQ (alcohol plus < control), alcohol exposure (control & alcohol plus < alcohol minus ), and cigarette (alcohol plus > control) and cannabis (alcohol plus > alcohol minus & control) use history. The groups did not differ on handedness score or gender distribution. We further report that the groups did not differ significantly on drug treatment order (χ 2 = 0.48, df = 2, p > 0.7) during the study.
RESULTS
Demographics
MID performance
Figure 1a below shows the mean MID accuracy (percent) for the two conditions in the alcohol minus , alcohol plus and control groups during the placebo and naltrexone sessions. A three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) by two (Condition: neutral versus win) repeated measures ANOVA showed a significant effect of condition (F = 46.3; df = 1, 78; p < 0.001-win > neutral) and a significant drug × group interaction (F = 4.04; df = 2, 78; p < 0.05). Follow-up analyses revealed that, across MID conditions, the alcohol plus group was significantly less accurate than both the alcohol minus (p < 0.001) and control (p < 0.01) groups during the placebo session only. Figure 1b below shows the mean MID reaction time (milliseconds) for the two conditions. The same ANOVA demonstrated a significant effect of condition (F = 63.6; df = 1, 78; p < 0.001-win < neutral) and a significant drug × group interaction (F = 4.07; df = 2, 78; p < 0.05). Follow-up analyses revealed that, across MID conditions, the alcohol plus group was significantly slower than both the alcohol minus and controls groups (p < 0.05) during the placebo session only. Finally, Fig. 1c shows the computed index of the RMV. A three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA showed no effect of drug (F = 0.61; df = 1, 78; p = 0.43), group (F = 0.45; df = 2, 78; p = 0.63) or a drug × group interaction (F = 0.62; df = 2, 78; p = 0.53) on this index, however.
Functional MRI
All three groups demonstrated statistically significant activation patterns across fronto-striatal regions during the placebo and naltrexone challenges for the win anticipation > neutral anticipation contrast at a whole a) b) c)
Figure 1 MID task performance in the alcohol minus , alcohol plus and control groups during the placebo and naltrexone sessions for a) mean percentage accuracy; b) mean reaction time and c) relative motivational value (RMV). Accuracy and reaction time data were analysed using a three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) by two (Condition: neutral versus win) repeated measures ANOVA. RMV was analysed using a three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA. MID accuracy:
••• p < 0.001-Win > Neutral; **p < 0.01-alcohol plus < control on placebo; ***p < 0.001-alcohol plus < alcohol minus on placebo. MID reaction time:
••• p < 0.001-Win < Neutral; *p < 0.05-alcohol plus < alcohol minus brain level (see Supplementary Figs 1 & 2) . As we did not observe any significant group × drug interactions for a three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) whole brain cluster-based repeated measures ANOVA, we decided to collapse across the two substance groups in order to increase the power to detect clusters related to a main effect of group. The two (Group: alcohol minus & alcohol plus combined versus control) by two (Drug: placebo versus naltrexone) whole brain cluster-based repeated measures ANOVA analyses showed a significant main effect for group (see Supplementary Fig. 3 ), but did not reveal a significant main effect for drug or a drug × group interaction. Table 2 shows the cluster-based statistics from this ANOVA group effect, which comprised 12 separate clusters covering cerebellar, occipital, temporal, frontal and striatal regions. In order to assess the direction of the observed group effect, we performed three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA analyses on the mean BOLD signal change within each of the group ANOVA zF-statistic clusters. These were performed in order to reveal whether the alcohol minus and alcohol plus groups independently contributed to the main ANOVA group effect.
In the left orbitofrontal cortex (OFC) cluster, there was a main effect of group (F = 5.25; df = 2, 78; p < 0.01), which revealed that only the alcohol plus group was significantly lower than the control group (p < 0.01- Fig. 2a ) in this region. Within the right inferior frontal gyrus (IFG)/insula cluster, however, a main effect of group (F = 4.25; df = 2, 78; p < 0.05) showed that there was a significant BOLD signal reduction in both the alcohol minus and alcohol plus groups (p < 0.05- Fig. 2b ) compared to the control group. There was also a main effect of group in the left (F = 4.17; df = 2, 78; p < 0.05) and right (F = 4.12; df = 2, 78; p < 0.05) ventral caudate/nucleus accumbens (NAcc) showing that the alcohol minus group (p < 0.05), and to a greater degree, the alcohol plus group (p < 0.01) exhibited a significantly lower BOLD signal change than the control group across these striatal regions ( Fig. 3a & b) .
Additionally, there was a significant effect of group in the right frontal pole cluster (F = 6.23; df = 2, 78; p < 0.05-alcohol minus < control, p < 0.05; alcohol plus < control, p < 0.01); right cerebellum cluster (F = 3.5; df = 2, 78; p < 0.05-alcohol plus < control, p < 0.05); right parahippocampal gyrus cluster (F = 6.40; df = 2, 78; p < 0.01-alcohol minus < control, p < 0.05; alcohol plus < control, p < 0.01); right supramarginal gyrus cluster (F = 4.10; df = 2, 78; p < 0.05-alcohol minus and alcohol plus < control, p < 0.05); left middle temporal gyrus/parahippocampal gyrus cluster (F = 7.73; df = 2, 78; p < 0.01-alcohol minus < control, p < 0.05; alcohol plus < control, p < 0.001) and the left occipital fusiform gyrus cluster (F = 3.32; df = 2, 78; p < 0.05-alcohol plus < control, p < 0.05). We did not, however, observe a significant effect of group in either the left (F = 2.21; df = 2, 78; p < 0.1) or right (F = 2.25; df = 2, 78; p < 0.09) anterior cingulate cortex (ACC) clusters, suggesting that the original observed group effect in this region was because of a conflation of the alcohol minus and alcohol plus groups. In order to confirm this, we collapsed across the two groups and conducted a two (Group: alcohol minus & alcohol plus combined Table 2 ANOVA group effect clusters from a two (Group: alcohol minus & alcohol plus combined versus control) by two (Drug: placebo versus naltrexone) whole-brain cluster-based repeated measures ANOVA for the win anticipation > neutral anticipation contrast. Statistical images were first thresholded using clusters determined by Z > 2.3 with a corrected cluster significance level of p < 0.05. The P value corresponding to the maximum zF-statistic within each cluster is shown. Co-ordinates are represented in Montreal Neurological Institute (MNI) space. versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA to verify a significant effect of group in the left (F = 4.88; df = 1, 79; p < 0.5 -alcohol minus & alcohol plus combined < control- Fig.  4a ) and right (F = 5.06; df = 1, 79; p < 0.5-alcohol minus & alcohol plus combined < control- Fig. 4b ) ACC clusters. The same whole brain cluster-based repeated measures ANOVA analysis also revealed a significant main effect of group for the win miss > neutral miss contrast in the left insula (140 voxels; x = À42; y = 14; z = À12; zF = 3.72; df = 1, 79; p < 0.001) and the right ACC (415 voxels; x = 4; y = 44; z = 4; zF = 3.51; df = 1, 79; p < 0.001) only. As with the anticipation contrast, we additionally conducted the same three by two repeated measures ANOVA on the mean BOLD signal change within these two clusters. There was a significant effect of group in the left insula (F = 4.51; df = 2, 78; p < 0.05 -alcohol minus and alcohol plus < control, p < 0.05- Fig. 5a ) and in the right ACC (F = 4.21; df = 2, 78; p < 0.05-alcohol minus and alcohol plus < control, p < 0.05- Fig. 5b) , showing that the alcohol minus and alcohol plus groups independently contributed to the main ANOVA group effect. This same analysis also showed a trend towards a drug effect in both the insula (F = 2.87; df = 1, 78; p = 0.09) and ACC (F = 3.13; df = 1, 78; p = 0.08) clusters, likely driven by the direction of signal change on the naltrexone session in the alcohol minus and alcohol plus groups. Therefore, we additionally performed post hoc within group paired t-test analyses and showed that in the alcohol plus group only, there was an attenuation of the BOLD signal change during the naltrexone compared to the placebo session in both the insula (Àt = 2.12; df = 24, p < 0.05) and the ACC (Àt = 2.26; df = 24, p < 0.05) clusters. There were no significant main effects for the win hit > neutral hit contrast.
Voxel
a) b)
Figure 2 Three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA on the mean BOLD signal change scores within the group ANOVA zF-statistic clusters for the win anticipation > neutral anticipation contrast. Results showed that the alcohol plus group had significantly less activation change in a) the left OFC compared to the control group (**p < 0.01) and that the control group had significantly greater activation change in b) the right IFG/insula compared to both the alcohol minus and alcohol plus groups (*p < 0.05). Data are expressed as means ± SEM. Co-ordinates are represented in Montreal Neurological Institute (MNI) space. OFC: orbitofrontal cortex; IFG: inferior frontal gyrus
DISCUSSION
This study set out to examine fronto-striatal activation during reward anticipation and instrumental responding in long-term abstinent alcoholic and alcoholic polysubstance-dependent individuals in order to evaluate the acute modulating effects of MOR blockade on these processes. The study showed that the alcohol plus group exhibited slower and less accurate instrumental responding across MID conditions compared to both the alcohol minus and control groups during the placebo session, an effect that was less evident after naltrexone but with no absolute improvement in speed and accuracy of responding as a result of drug treatment. The study additionally showed, however, that while there were no effects on the RMV for rewards, there were disturbances within fronto-striatal regions during reward anticipation and 'missed' rewards in both substance dependent groups that were not reliably remediated by acute naltrexone treatment.
The observed slower and less accurate responding of the alcohol plus group may suggest a low degree of motivation during the sustained cognitive demands of general instrumental effort. Using a behavioural motivational index that specifically reflects a higher relative value for reward incentives during instrumental responding, however, we observed no difference between groups or any effects of naltrexone. The apparent remediation produced by acute naltrexone in the alcohol plus group seems most likely to be a consequence of changes in response to naltrexone in the comparison groups as there was little evidence of absolute improvements in behavioural functioning produced by naltrexone in the alcohol plus group.
Reduced BOLD activation changes in the alcohol plus group
Under conditions of reward anticipation, the alcohol plus group exhibited significantly lower activation change in the OFC compared with that of the control group across a) b)
Figure 3 Three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA on the mean BOLD signal change scores within the group ANOVA zF-statistic clusters for the win anticipation > neutral anticipation contrast. Results showed that the control group had significantly greater activation change in a) the left caudate/NAcc compared to both the alcohol minus (*p < 0.05) and alcohol plus (**p < 0.01) groups and in b) the right caudate/NAcc compared to both the alcohol minus (*p < 0.05) and alcohol plus (**p < 0.01) groups. Data are expressed as means ± SEM. Co-ordinates are represented in Montreal Neurological Institute (MNI) space. NAcc: nucleus accumbens drug treatments. There is previous evidence of hypofunctioning in the OFC (London et al. 2000) , particularly during abstinence (Volkow et al. 1992) . The OFC has important functional connections with the striatum (Volkow & Fowler 2000) and is known to code the motivational value of stimuli (Koeneke et al. 2008) . The OFC also contains a high number of MORs (Gorelick et al. 2005) , suggesting that any disturbance to the brain's opioid system might be modulated by naltrexone. The current results, however, provide no evidence for an acute modulatory effect in the OFC, instead suggesting that disturbances within striato-orbitofrontal circuitry that subserves reward prediction and motivational processes, are sustained in long-term polysubstance, but not alcohol, abstinence.
Independent BOLD activation reductions in the alcohol minus and alcohol plus groups Compared to controls, the alcohol minus , and to a greater degree, the alcohol plus group, exhibited reduced bilateral ventral caudate/NAcc activation in response to the anticipation of potential monetary rewards. The current result concurs with previous research findings of altered striatal activity for non-drug rewards in substance dependence (Wrase et al. 2007; Diekhof, Falkai, & Gruber 2008; Buhler et al. 2010; Peters et al. 2011; Bustamante et al. 2014; Gradin et al. 2014) and may be consistent with a sustained striatal reward deficiency syndrome (Blum et al. 2000; Koob et al. 2004) in long-term substance abstinence. There are also high levels of MORs in the caudate (Arvidsson et al. 1995) , making this region a credible target for modulation with naltrexone. The current findings, however, do not appear to support a remediating effect of naltrexone in this particular behavioural context.
The current study also found that both the alcohol minus and alcohol plus groups demonstrated reduced activation changes compared with controls in the frontal pole and IFG/insula regions during reward anticipation. The PFC represents both cognitive and rewardrelated information processing (Watanabe & Sakagami 2007) , whereas the insula is implicated in reward and risk prediction (Preuschoff, Quartz, & Bossaerts 2008) and addiction relapse (Paulus, Tapert, & Schuckit 2005; Seo et al. 2013) , possibly because of its role in awareness of interoceptive (i.e. bodily) states (Critchley et al. 2004) . The current findings may, therefore, suggest that in long- term alcohol and polysubstance abstinence, there are sustained disturbances within a network of regions that function to integrate the cognitive interpretation of motivational drives (Goldstein et al. 2007 ) and other emotional and interoceptive states.
We also observed that the alcohol minus and alcohol plus groups exhibited reduced activation changes compared with controls in the anterior insula, and notably, the rostral ACC (rACC) during 'missed' rewards. The rACC has been labelled as the 'affective division' of the cingulate (Devinsky, Morrell, & Vogt 1995; Bush, Luu, & Posner 2000) , through processing the emotional components of errors (van Veen & Carter 2002; Luu et al. 2003) . The observed decrease in error-related rACC and insula activation may have resulted from decreases in arousal during misses, an effect that was apparently exacerbated by acute opioid blockade with naltrexone. This blunting of error-related signalling by naltrexone in substance abusers may have clinical implications, where arousal and conflict monitoring are necessary responses to violations in prediction that require adjustments to ongoing behaviour during treatment. The effects of naltrexone in the insula and ACC, however, may encourage further investigations regarding the effects of opioid blockade on error-related neural responses in addiction populations.
Interdependent BOLD activation reductions in the alcohol minus and alcohol plus groups When combined, the alcohol minus and alcohol plus groups exhibited reduced activations in the ACC during the anticipation of monetary reward compared to controls that were not modulated by naltrexone. The ACC has been implicated in addiction and its cognitive sequelae Peoples 2002; Volkow et al. 2002) , with disturbances in this region reported in a number of abstinent substance abusing populations Eldreth et al. 2004; Salloum et al. 2007; Nestor et al. 2011) . One of these differences was observed for the caudal dorsal ACC (cdACC), a region involved in processing the value of actions, motivation and expected outcomes under conditions of reward (Kouneiher, Charron, & Koechlin 2009 ). This may suggest that neural processing within a motivational and reward prediction cognitive network remains compromised in long-term substance abstinence.
a) b)
Figure 5 Three (Group: alcohol minus versus alcohol plus versus control) by two (Drug: placebo versus naltrexone) repeated measures ANOVA on the mean BOLD signal change scores within the two group ANOVA zF-statistic clusters for the win miss > neutral miss contrast. Results showed that the control group had significantly greater activation change in a) the left insula (*p < 0.05) and in b) the right anterior cingulate cortex (*p < 0.05) compared to both the alcohol minus and alcohol plus groups. Within group analyses also revealed that the alcohol plus group had a greater BOLD signal reduction on naltrexone compared to placebo in both these regions ( Limitations of the current study include a lack of complete matching of groups with respect to age, cannabis and cigarette use, anxiety and mood measures, which means we cannot unequivocally dismiss their potential influence on altered reward processing in fronto-striatal circuitry of both the alcohol minus and alcohol plus groups. Furthermore, we did not thoroughly assess alcohol and drug craving at each session across the groups, which may have had a possible influence on our metrics of motivation and reward processing. Moreover, dependence on (and abstinent from) multiple and varying substances of abuse in the alcohol plus group underpowered us to statistically examine the influence of these measures on indices of motivation and reward processing. While our groups were well matched on the distribution of gender, the small number of females in each group did not permit us to examine the influence of gender effects on the neurobiology of reward and motivational processes in the two substance-dependent groups. The reduced number of loss trials in our MID task also meant we were unable to examine the neural correlates of loss anticipation and outcome, where sensitivity to punishment may well have implications for treatment and drug relapse.
In summary, the current study set out to map the impact of MOR blockade upon neural networks disrupted in substance dependence and has demonstrated evidence of sustained disturbances within fronto-striatal regions of long-term abstinent alcoholics and polysubstancedependent individuals. It has also shown that acute naltrexone treatment produced a relative minor amelioration of behavioural performance on a monetary incentive delay task in an alcoholic, polydrug abuser group (alcohol plus ), but not in a group of patients with 'pure' alcoholic abuse (alcohol minus ). Moreover, naltrexone was unable to reverse neural changes in frontostriatal systems associated with the MID task, possibly suggesting the potential insensitivity of this task for elucidating possible therapeutic effects on neural biomarkers in future experimental medicine studies.
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